respiratory syncytial virus immune globulin


Also found in: Acronyms.

respiratory syncytial virus immune globulin (RSV-IGIV)

an immune serum.
indications It is used in children less than 2 years of age with bronchopulmonary dysplasia or in those born prematurely to prevent serious lower respiratory tract infection caused by respiratory syncytial virus.
contraindications Factors that prohibit its use are hypersensitivity to this drug or to other human immunoglobulin preparations and IgA deficiency.
adverse effects Life-threatening effects are respiratory distress, hypoxia, anaphylaxis, and angioneurotic edema. Other adverse effects are tachypnea, rales, wheezing, fever, hypertension, tachycardia, fluid overload, diarrhea, gastroenteritis, vomiting, rash, overdose effect, and inflammation at the injection site.
References in periodicals archive ?
those at high risk for severe complications or who are seriously ill with this infection) (8); respiratory syncytial virus immune globulin intravenous (human) for high-risk patients was licensed for use in January 1996 (9).
Reduction of RSV hospitalization among premature infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis.
In one study, monthly respiratory syncytial virus immune globulin (RSVIG) significantly decreased the number of AOM episodes due to RSV, the most important viral etiologic agent.
Food and Drug Administration (FDA) has approved the use of respiratory syncytial virus immune globulin (RespiGam [TM]) to prevent RSV infection in infants at high risk of complications from the illness.

Full browser ?